Natera Inc is a biotechnology company that focuses on providing innovative genetic testing services for various medical applications. The company specializes in non-invasive prenatal testing, environmental DNA analysis, and oncology, utilizing advanced genetic insights to aid in disease detection and management. By leveraging its proprietary technology and bioinformatics, Natera aims to improve patient outcomes and facilitate personalized medicine through comprehensive genomic solutions that empower healthcare providers and patients alike. Read More
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company’s novel SNP-informed deep sequencing technology, Panorama NIPT is now backed by clinically-validated performance data in samples with low fetal fraction, enabling a no-call rate of 0.5%.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place May 29–June 2 in Chicago, IL.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milestone in the company’s continued growth and mission to improve outcomes for patients with cancer and other serious diseases.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-a...
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 202...
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women’s health and another record quarter
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696....
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2026, with sales up 38.8% year on year to $696.6 million. Its GA...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026.
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday afternoon. Here’s what to expect. Natera beat analysts’ reven...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Natera has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6%. The stock now trades at $208.20, marking a 10.5% gain....
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL).
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera’s litigation with ArcherDx and Invitae.
